Chaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases
Research
Prof. Aaron Lerner February ,2022 1976 Tel Aviv University, Tel Aviv, Israel M.D 1977-1982 Carmel Medical Center, Haifa, Israel Certified Pediatrician 1982-4 State University of New York, New York, U.S.A. Certified Pediatric Gastroenterology 1986-7 Rambam Medical Center, Haifa, Israel Certified Gastroenterologist 2005-2015 Head, Pediatric Gastroenterology Unit, Carmel Medical Center 2004-5 State University of North Carolina, Chapel Hill, N.C, U.S.A Visiting Professor 2014-2020 Aesku.Kipp Research Institute, Wendelsheim, Germany Visiting Professor 2020- The Zabludowicz Research Center for Autoimmune Diseases. Current academic position: 2020- Chaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases, Tel- Hashomer, Israel Scientific interests: Mucosal immunology, autoimmunity, diagnostic serology, Celiac disease, nutritional deficiencies, industrial food additives, intestinal permeability, microbial transglutaminase, microbiome/ dysbiome/ virome, gluten, and gliadin peptides. No of peer-reviewed scientific publications: 330 Aaronlerner1948@gmail.com

Moderator of 1 Session

Date
Mon, 13.06.2022
Session Time
14:30 - 16:30
Room
ALEXANDRA TRIANTI
Session Type
PARALLEL SESSIONS

Presenter of 5 Presentations

THE REPERTOIRE OF AUTOANTIBODIES IN CELIAC DISEASE: ANY NEW ONE? (ID 905)

Date
Mon, 13.06.2022
Session Time
08:00 - 10:00
Session Type
PLENARY SESSIONS
Room
ALEXANDRA TRIANTI
Lecture Time
09:00 - 09:30

MICROBIAL TRANSGLUTAMINASE IS A NEW POTENTIAL INDUCER OF AUTOIMMUNE DISEASE (ID 900)

Date
Sun, 12.06.2022
Session Time
17:00 - 19:00
Session Type
PARALLEL SESSIONS
Room
ALEXANDRA TRIANTI
Lecture Time
17:15 - 17:30

GLUTEN AND NEURODEGENERATIVE DISEASES (ID 866)

Date
Sun, 12.06.2022
Session Time
10:30 - 12:30
Session Type
PARALLEL SESSIONS
Room
MC2 HALL
Lecture Time
10:45 - 11:00

O053 - GLUTEN-FREE DIET IN NON-CELIAC AUOIMMUNE DISEASES (ID 89)

Date
Tue, 28.02.2023
Session Time
17:00 - 19:00
Session Type
PARALLEL SESSIONS
Room
MC2 HALL
Lecture Time
17:55 - 18:05

Abstract

Background and Aims

Background: A discrepancy exists between the worldwide increased wheat consumption and its popularity and between the scientific observations on the side effects of gluten, the major protein in wheat. Autoimmune disease (AD) incidence increases in parallel. Recently, gluten has been associated with autoimmune properties and even as a contributor to neurodegenerative conditions. In addition, celiac disease is associated with numerous ADs.

Methods

Methods: PubMed/MEDLINE, Web of Sciences, LILACS and Scielo, 1960-2021, were searched, using the keywords of various ADs and gluten-free diet (GFD). We selected non-celiac ADs, where GFD was studied.

Results

Results: 83 articles in which GFD was used to treat 29 ADs were found. These diseases spanned rheumatic, skin, muscle, connective tissue, intestinal, hepatic and biliary, pancreatic, thyroidal, adrenal, hematological, cardiac, kidney, ocular, gynecological, and cerebral as well. Age ranged from 9 months to 69 years. ADs duration between 0 to 20 ± 13 years. Duration of GFD varied between 1 month to 9 years. Interestingly, improvement of ADs after GFD was observed in 66 out of the 83 studies (79.5%), in 15.7% no changes were seen, in 3.6% worsening was seen and in 2.4% this data was not available. Symptomatic improvement was noticed in 911/1408 patients.

Conclusions

Conclusion: Based on the results, gluten withdrawal was efficient in about 80% of the screened ADs. It might represent a new nutritional therapeutic strategy for autoimmunity. Gluten-induced adverse effects, dysbiosis, leaky gut, cross-linked antibodies, and sequence homology might be some of the pathophysiological mechanisms for the beneficial effect of gluten restriction.

Hide

O113 - MICROBIAL TRANSGLUTAMINASE IS A NEW ENVIRONMENTAL INDUCER OF AUTOIMMUNE DISEASES: POTENTIAL PATHOGENISITY (ID 92)

Date
Mon, 13.06.2022
Session Time
10:30 - 12:30
Session Type
PARALLEL SESSIONS
Room
MC2 HALL
Lecture Time
11:40 - 11:50

Abstract

Background and Aims

Background: Microbial transglutaminase (mTG) is a survival mechanism for intestinal luminal prokaryotes and is heavily used in the processed food industry. Lately, mTG was suspected as a new environmental inducer of celiac disease (CD), other autoimmune (ADs), and neurodegenerative conditions. Intriguingly, gluten is a prime substrate for transamidation by the mTG peptide cross-linker. Summarize are the potential pathogenic observations, mechanisms, and pathways in mTG-ADs relationship.

Methods

Methods: A literature search was performed, using PubMed, Google, and Cochrane Library databases, between 2000-2021, searching for mTG and various ADs interactions

Results

Results: MTG-gliadin cross-linked complexes are immunogenic in CD. The enzyme enhances intestinal permeability, suppresses mechanical (mucus) and immunologic (anti phagocytic) enteric protective barriers, stimulates luminal bacterial growth, and augments uptake of gliadin peptide. Interestingly, mTG and gliadin molecules are co-transcytosed through the enterocytes and deposited sub-epithelially, mucosal dendritic cells surface TG induce gliadin endocytosis and mTG treated wheat products are immunoreactive in CD. Gliadin peptides are circulating in the blood and mTG trans passes the mucosal barriers. The resulting immunogenic complexes might be created in the bakeries, food processed industries, enteric lumen, and even in the sub-epithelial compartment, facing the local immune systems.

Conclusions

Conclusions: The regulatory and food safety authorities should reconsider its GRAS status as a processing aid to change it to a food ingredient that should be labeled and thoroughly evaluated for toxicity and public health safety. If substantiated it will affect food product labeling, processed food additive policies, regulatory authorities’ product control, consumer health education, and public health safety.

Hide